Paragonix Data Highlights Precision Preservation as Lung Transplant Standard
Event summary
- Clinical research presented at the 2026 ISHLT Annual Meeting analyzed data from 499 adult lung transplant recipients between February 2021 and April 2025.
- Lungs preserved within a 6-8°C temperature range demonstrated significantly improved outcomes (reduced rejection, lower intervention burden) compared to the 8-10°C range.
- The BAROguard System, which manages airway pressure, showed reduced need for mechanical support and airway inflammation, even in higher-risk transplant scenarios.
- Data from transport distances over 500 nautical miles (simulating air travel) showed BAROguard improved outcomes, including a 24% reduction in hospital length of stay.
The big picture
Paragonix's findings underscore a growing trend toward personalized and data-driven approaches in organ transplantation. The company's focus on actively managing physiological variables during preservation addresses a critical bottleneck in the transplant process – organ viability – and positions it to benefit from the increasing demand for transplantable organs. The data also highlights the potential for technology to mitigate the impact of 'time-shifted' organs, expanding the donor pool and improving access to life-saving procedures.
What we're watching
- Adoption Rate
- The pace at which transplant centers adopt Paragonix’s precision preservation technologies will determine the company’s ability to capture a larger share of the lung transplant market, which is currently limited by organ availability.
- Reimbursement
- How payers respond to the demonstrated clinical benefits of these technologies will be crucial; favorable reimbursement policies are needed to drive widespread adoption and revenue growth.
- Competitive Landscape
- The emergence of competing preservation technologies or alternative approaches to lung transplantation could erode Paragonix’s market position and necessitate further innovation.
Related topics